Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY AI Verdict: PROCEED
Price: $530.76 Analyst target: $571.46 Upside: 7.67%
VRTX is in a clear uptrend (close 523.93 > SMA20 503.38 > SMA50 472.19 > SMA200 424.53) with neutral momentum (RSI 61.5, Stoch 48.6) and room below the 560.25 resistance/52-week high. The likely catalyst is positive Phase 3 kidney data (povetacicept cutting proteinuria 52%, RAINIER results), reflected in Somewhat-Bullish sentiment (0.17, 70 bullish vs 16 bearish of 162 articles); fundamentals are solid (35% margin, 12.5% revenue growth, forward P/E 24.1, target 571).
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.